Brain Mechanisms in Acute and Chronic Depression Vary, According to New Research

A new study investigating neuroinflammation in the ventral tegmental area (VTA) of the brain, a small, midbrain dopaminergic region, has found that acute and chronic depression are associated with distinct pathophysiological mechanisms. The findings from this new study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published by Elsevier, help clarify the VTA’s role as a potential target for developing more targeted and state-specific treatments for depression.

Depression affects approximately 300 million individuals worldwide, making it a leading cause of disability. Inflammation has consistently been linked to depression in both clinical and population studies. Periods of prolonged stress, often preceding depression, can induce acute and, in severe cases, chronic inflammation in the brain. Previous research suggests that inflammatory processes can disrupt the synthesis, release, and reuptake of dopamine, the key neurotransmitter central to the brain’s reward system. Disruptions within this reward circuitry are thought to underlie core depressive symptoms such as anhedonia and low motivation.

“Our study focused on the VTA because it is at the core of the mesocortical and mesolimbic systems, which are both strongly associated with depression due to their central roles in reward processing, motivation, and emotional regulation. However, because of its small size and complex structure, the VTA has been relatively neglected in neuroimaging research,” notes co-lead investigator Lena K.L. Oestreich, PhD, School of Psychology, and the Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia.

The researchers wanted to determine whether the VTA could reveal biological differences in individuals with a history of depression (chronic state) or current depressive symptoms (acute state). They analyzed MRI markers sensitive to inflammation and brain microstructure, specifically measures of extracellular and intracellular water content in the VTA, using a large and diverse sample from 32,495 UK Biobank participants, including 3,807 individuals with International Classification of Diseases (ICD-10)-diagnosed depression.

Co-lead investigator Sarah Khalife, PhD candidate, School of Psychology, The University of Queensland, Brisbane, Australia, explains, “We found that individuals with a history of major depression showed higher MRI markers associated with neuroinflammation (free water and isotropic volume fraction) in the VTA, suggesting increased extracellular inflammatory processes. In contrast, current depressive symptom severity was associated with distinct microstructural changes (higher intracellular volume fraction and orientation dispersion, but lower isotropic volume fraction), indicating that acute and chronic depression may involve different underlying pathophysiological mechanisms.”

Depression is a highly heterogeneous disorder influenced by numerous factors, including sex, lifestyle factors, genetic predisposition, and metabolic variables such as BMI. The results of this analysis underscore the complex interplay between neuroinflammation, lifestyle factors, and depressive symptoms, suggesting that future studies should consider these factors in more detail to fully understand the multifactorial nature of depression.

“By focusing on the VTA and using updated brainstem atlases, the investigators were able to map the VTA more precisely and contribute to the limited body of human imaging research on this region, illuminating the VTA’s role as a potential future therapeutic target for depression,” concludes Editor-in-Chief of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging Cameron S. Carter, MD, University of California Irvine School of Medicine.

Notes for editors

The article is "MRI-Derived Markers of Acute and Chronic Inflammatory Processes in the VTA Associated with Depression," by Sarah Khalife, Steffen Bollmann, Andrew Zalesky, and Lena K.L. Oestreich (https://doi.org/10.1016/j.bpsc.2025.09.003). It appears online in online in advance of volume 11, issue 2 (February 2026) of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published by Elsevier.

The article is openly available athttps://www.biologicalpsychiatrycnni.org/article/S2451-9022(25)00267-8/fulltext.

Copies of this paper are also available to credentialed journalists upon request; please contact Rhiannon Bugno at [email protected]. Journalists wishing to interview the study’s authors should contact Lena K.L. Oestreich, PhD, School of Psychology, and the Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, at [email protected].

The authors’ affiliations and disclosures of financial and conflicts of interest are available in the article.

Cameron S. Carter, MD, is Chair of the Department of Psychiatry & Human Behavior at the University of California Irvine School of Medicine. His disclosures of financial and conflicts of interest are available here.

Lena Oestreich was supported by a National Health and Medical Research Council (NHMRC) Investigator grant (2007718), a strategic award from the School of Psychology, and a start-up fund from the Australian Institute for Bioengineering and Nanotechnolgy at the University of Queensland.

About Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is an official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal focuses on studies using the tools and constructs of cognitive neuroscience, including the full range of non-invasive neuroimaging and human extra- and intracranial physiological recording methodologies. It publishes both basic and clinical studies, including those that incorporate genetic data, pharmacological challenges, and computational modeling approaches. The 2024 Journal Impact Factor^TM score, from Clarivate, for Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is 4.8.www.sobp.org/bpcnni

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELX의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.